GENZ-882706 is primarily utilized in medical research and drug development for the treatment of Acute Myeloid Leukemia (AML). It targets the inhibition of enzymes involved in the growth and survival of cancer cells. Studies indicate its potential to reduce cancer cell proliferation and promote the death of abnormal cells. Additionally, it is being evaluated for efficacy and safety in combination with other therapies to enhance treatment outcomes. GENZ-882706 is currently in clinical trials and is expected to offer a novel option for AML patients in the future.